Equity research notes
Single-stock coverage with a thesis, a defensible valuation and the risks that would break it. Not a summary of the management call — an independent view.
Broker research answers to the broker. Corporate-sponsored research answers to the mandate. Telegrams answer to the referral commission. Ours answers to your subscription fee — nothing else. SEBI-registered, CA-led, conflict-free by structure.
Not abstract pain points. The exact moments that led people to stop trusting the research they had — and what changed.
“You acted on a "Strong Buy — Target ₹580" note. The stock dropped 34% over the next year. You later found, in footnote 19, that the analyst's firm had an active IB mandate with that company. The report never mentioned it upfront.”
We have one source of income: your subscription fee. No brokerage desk, no corporate mandates, no distribution commissions. By regulation (SEBI RA Reg. 2014), every report we publish declares analyst holdings, any conflicts and the rating methodology — at the top of the document, not in a footnote.
Research that is structurally incapable of recommending something because a deal depends on it.
Over time, the only research worth reading is research that answers to you.
“Results dropped at 6:30 PM. You wanted to know if your thesis still held. Your broker published a note at 11 AM the following day — by which point the stock had already moved 7.4% at the open on what the market already knew.”
We publish earnings breakdowns the same evening — typically within 3 hours of the results filing. What the headline number says, what management didn't say in the call, what changed versus the prior quarter thesis, and whether the original view holds.
You know before the open what your position means — not after the market has already priced it.
A 12-hour lead on earnings analysis compounds into position decisions made on facts, not price action.
“Your main holding is KPIT Technologies. Your broker's research team covers 250 stocks — KPIT isn't one of them. The only coverage you found was from a firm that stopped updating it 10 months ago. You've been making decisions on stale analysis.”
Research subscribers submit one coverage request per month. We analyse the stock — fundamentals, valuation, risk factors, thesis — and deliver a full note within 7 business days. You pick what gets covered.
Independent analysis on the stock you actually own. Not whatever stock 200 analysts collectively think is interesting.
A growing library of coverage on your actual portfolio, updated when it matters.
“The research note was 47 pages. Pages 1–32 were data you could have found in the annual report. Pages 33–44 were five valuation scenarios with no guidance on which to believe. Page 45 was a one-line recommendation, hedged with three caveats. You still don't know what to do.”
We write for the decision. The thesis is on page one: what we think, why we think it, what would make us wrong. Primary sources are cited. Every assumption is stated. Long-form when depth is warranted — but never a data dump that buries the view.
30 minutes to a clear position, not 30 minutes searching for what the analyst actually believes.
Research you can read, verify and act on builds a relationship with the analyst's thinking — not just with their conclusion.
“You've been a subscriber for 4 months. A position you want to check has had 3 reports and 2 updates since you joined. One arrived via email, one via a PDF, one was mentioned in a newsletter. You can't find the update from last month.”
Every call and report published under your subscription lives in the DRIP client portal — searchable, with Entry / Target / Stop on every live recommendation. No hunting through your inbox. No PDFs sent over WhatsApp.
Your entire research history in one place, current as of today.
A compounding decision log — every call made, every outcome recorded, the track record visible.
Good research is repeatable. Ours follows the same process every time — so when we're wrong, you can see exactly where the reasoning broke. That transparency matters more than being right once by accident.
Annual reports, exchange filings, cash flow statements — not second-hand tips or management presentations. If we can't cite it, we don't say it.
Every claim is sourced, every assumption is stated. You can check our work. We expect you to. If we're wrong, the reasoning is visible and you can see exactly where it broke.
We lead with what can go wrong and why, then size accordingly. Conviction without a clear risk case is just a guess with a good narrative.
Forensic accounting, DuPont analysis and valuation depth from a Chartered Accountant and CFA Program candidate — not a generalist content team rephrasing a management call.
Every piece carries the same discipline — primary sources, stated assumptions, disclosed conflicts. What changes is the scope.
Single-stock coverage with a thesis, a defensible valuation and the risks that would break it. Not a summary of the management call — an independent view.
How an industry makes money, who's winning and why, and what disrupts it. Written to inform a portfolio decision, not to fill a content calendar.
Same-day breakdown when results drop — what the number says, what management didn't say, and what it means for the thesis. Not a recap published 18 hours later.
Transparent, rules-based portfolios. Every entry and exit disclosed. Every rebalance explained. The track record is public — good and bad.
From DESVELADO ADVISORY PRIVATE LIMITED. Independent equity research on subscription — no broker desk, no mandate, no conflict. KYC required. No payment today.